Replies to post #97565 on Biotech Values

[DewDiligence]

Re: Who’s Who in All-Oral HCV Programs

i think the ribavirin column [in #msg-51502116] is misleading… gild and roche both have a lead-in portion of therapy without rib in some arms, but all pts will ultimately receive ribavirin.

I agree that the use of ribavirin varies considerably among the trials in question; however, there’s only so much information one can convey in a compact table, and that’s why I included links to the trial descriptions in clinicaltrials.gov.

given the main MOA of ribavirin is to prevent relapse, any exposure to ribavirin prior to an SVR endpoint doesn't mean much in assessing if ribavirin can be dropped from the regimen altogether

You state this as though it were fact rather than opinion, but it’s not. It may turn out that ribavirin is not uniquely relevant in preventing HCV relapse, but rather is just a weak DAA that mops up mutations to a drug like Telaprevir and can be replaced with a newer and better second-DAA agent.